Huntington’s Disease, (HD), is a genetic brain, (neurological), disease that affects both mind and body. Huntington’s Disease is characterized by an inability to control movements and an intellectual decline. The onset of HD symptoms usually occurs after 50 years of age.

A recent study, (Published by ELSEVIER, Biochimica et Biophysica Act 1762 [2006] 616-626), entitled “Dose Ranging and Efficacy Study of High Dose Coenzyme Q10 Formulations in Huntington’s Disease Mice” was conducted in Massachusetts at Boston University School of Medicine and the Bedford VA Medical Center in Bedford MA. The abstract of this study stated that “There is substantial evidence that a bioenergetic defect may play a role in the pathogenesis of Huntington’s Disease.” And, “a potential therapy for remediating defective energy metabolism is the mitochondrial cofactor, Coenzyme Q10 (CoQ10)”.

In this 2006 animal study using Huntington’s Disease mice, high dose CoQ10 “significantly extended survival” in mice, “the degree of which was dose and source-dependent”. The authors went on to say that the use of CoQ10 “resulted in a marked improvement in motor performance and grip strength”. The authors concluded by saying that their results suggest “that clinical trials using high dose CoQ10 in HD patients are warranted”.

There were two different CoQ10 formulations used in this study: Chemco CoQ10 USP Powder at 5,000mg per kg of the diet and Tishcon CoQ10 at 1,000mg per kg of the diet. (Different dosages were tested, but the authors found the best results at these levels.) The Tishcon CoQ10 used was HydroQSorb® CoQ10 powder which is the source of the bioenhanced CoQ10 in our ChewQ® chewable tablets.

Results of this study:

The Chemco and Tishcon CoQ10 formulations increased CoQ10 serum levels by 70 and 300 fold respectively.

The Chemco and Tishcon CoQ10 formulations increased CoQ10 brain levels by 22.4% and 52.1% respectively.

Even at the lower dose concentration of 1,000 mg/kg/day for the Tishcon CoQ10 formulation versus the 5,000 mg/kg/day for the powder CoQ10, the Tishcon HydroQSorb CoQ10 formulation extended survival rate in the mice by 25.3% greater than the powder CoQ10. Bottom line, the Tishcon CoQ10 formulation was as effective at a lower dose. In fact, the dose was only 1/5th of the powder CoQ10 dose! Put another way, the Tishcon CoQ10 formulation used 1/5th of the dose compared to the powder to achieve a 4 time greater increase in CoQ10 serum levels. Results like this make Tishcon’s HydroQSorb ChewQ® CoQ10 formulations ideal for patients needing High Dose CoQ10 supplementation.